Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ACRS)

Q: What does CUSIP 00461U105 represent in this 13F holders report?

CUSIP 00461U105 is the security identifier for ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share used to aggregate holder disclosures.

Q: How many institutions held ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share in Q2 2022?

112 institutional investors reported ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share for Q2 2022. Use the holders table for investor-level position and value details.

CUSIP: 00461U105

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class: Equity / Common Stock, $0.00001 par value per share
Shares outstanding: 121,058,810
Total 13F shares: 63,269,555
Share change: +4,048,205
Total reported value: $883,318,693
Put/Call ratio: 110%
Price per share: $13.96
Number of holders: 112
Value change: +$55,162,166
Number of buys: 58
Number of sells: 34

Quarterly Holders Quick Answers

What is CUSIP 00461U105?
CUSIP 00461U105 identifies ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2022
Previous quarter: Q1 2022

Recent filing periods for CUSIP 00461U105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	4.7%	5,730,253	$98,789,000	—	31 Mar 2022	13F
VR Adviser, LLC	13F	Company	3.8%	4,563,962	$78,683,000	—	31 Mar 2022	13F
BlackRock Finance, Inc.	13F	Company	3.3%	3,987,107	$68,738,000	—	31 Mar 2022	13F
BVF INC/IL	13F	Company	3.3%	3,976,543	$68,556,000	—	31 Mar 2022	13F
Rock Springs Capital Management LP	13F	Company	3.2%	3,865,034	$66,633,000	—	31 Mar 2022	13F
Foresite Capital Management IV, LLC	13F	Company	2.4%	2,899,034	$49,979,000	—	31 Mar 2022	13F
VANGUARD GROUP INC	13F	Company	2.3%	2,728,820	$47,045,000	—	31 Mar 2022	13F
Commodore Capital LP	13F	Company	1.9%	2,314,648	$39,905,000	—	31 Mar 2022	13F
Point72 Asset Management, L.P.	13F	Company	1.9%	2,277,100	$39,257,000	—	31 Mar 2022	13F
Holocene Advisors, LP	13F	Company	1.7%	2,060,918	$35,530,000	—	31 Mar 2022	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	1.5%	1,817,808	$31,339,000	—	31 Mar 2022	13F
ORBIMED ADVISORS LLC	13F	Company	1.3%	1,579,900	$27,237,000	—	31 Mar 2022	13F
DEUTSCHE BANK AG\	13F	Company	1.2%	1,467,103	$25,293,000	—	31 Mar 2022	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	1.2%	1,457,578	$25,129,000	—	31 Mar 2022	13F
Laurion Capital Management LP	13F	Company	1.2%	1,440,075	$24,827,000	—	31 Mar 2022	13F
Foresite Capital Management V, LLC	13F	Company	1%	1,258,243	$21,692,000	—	31 Mar 2022	13F
FMR LLC	13F	Company	1%	1,213,350	$20,918,000	—	31 Mar 2022	13F
TCG Crossover Management, LLC	13F	Company	0.95%	1,144,939	$19,739,000	—	31 Mar 2022	13F
STATE STREET CORP	13F	Company	0.89%	1,083,390	$18,678,000	—	31 Mar 2022	13F
CITADEL ADVISORS LLC	13F	Company	0.8%	972,200	$16,761,000	—	31 Mar 2022	13F
GREAT POINT PARTNERS LLC	13F	Company	0.78%	942,445	$16,248,000	—	31 Mar 2022	13F
Vivo Capital, LLC	13F	Company	0.74%	898,631	$15,492,000	—	31 Mar 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.7%	846,391	$14,591,000	—	31 Mar 2022	13F
Samsara BioCapital, LLC	13F	Company	0.66%	794,171	$13,692,000	—	31 Mar 2022	13F
Parkman Healthcare Partners LLC	13F	Company	0.55%	668,098	$11,518,000	—	31 Mar 2022	13F
Aisling Capital Management LP	13F	Company	0.52%	634,455	$10,938,000	—	31 Mar 2022	13F
Assenagon Asset Management S.A.	13F	Company	0.42%	507,435	$8,748,000	—	31 Mar 2022	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.39%	472,760	$8,150,000	—	31 Mar 2022	13F
NORTHERN TRUST CORP	13F	Company	0.39%	470,166	$8,106,000	—	31 Mar 2022	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.35%	425,000	$7,327,000	—	31 Mar 2022	13F
Frazier Life Sciences Management, L.P.	13F	Company	0.34%	408,329	$7,040,000	—	31 Mar 2022	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.32%	383,239	$6,607,000	—	31 Mar 2022	13F
Nuveen Asset Management, LLC	13F	Company	0.26%	317,540	$5,122,000	—	31 Mar 2022	13F
SILVERARC CAPITAL MANAGEMENT, LLC	13F	Company	0.23%	275,333	$4,747,000	—	31 Mar 2022	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.21%	258,459	$4,456,000	—	31 Mar 2022	13F
Verition Fund Management LLC	13F	Company	0.21%	255,478	$4,404,000	—	31 Mar 2022	13F
Integral Health Asset Management, LLC	13F	Company	0.2%	238,000	$4,103,000	—	31 Mar 2022	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.18%	217,600	$3,751,000	—	31 Mar 2022	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.17%	209,636	$3,614,000	—	31 Mar 2022	13F
Bank of New York Mellon Corp	13F	Company	0.15%	185,596	$3,200,000	—	31 Mar 2022	13F
HighVista Strategies LLC	13F	Company	0.13%	158,243	$2,728,000	—	31 Mar 2022	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.11%	133,068	$2,295,000	—	31 Mar 2022	13F
Ghost Tree Capital, LLC	13F	Company	0.1%	125,000	$2,155,000	—	31 Mar 2022	13F
Swiss National Bank	13F	Company	0.09%	108,500	$1,871,000	—	31 Mar 2022	13F
Affinity Asset Advisors, LLC	13F	Company	0.08%	100,000	$1,724,000	—	31 Mar 2022	13F
Allianz Asset Management GmbH	13F	Company	0.07%	81,965	$1,413,000	—	31 Mar 2022	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.06%	76,052	$1,311,000	—	31 Mar 2022	13F
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	13F	Company	0.06%	66,814	$1,152,000	—	31 Mar 2022	13F
HighTower Advisors, LLC	13F	Company	0.05%	63,299	$1,092,000	—	31 Mar 2022	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0.05%	60,986	$1,051,000	—	31 Mar 2022	13F

Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ACRS) as of Q2 2022

As of 30 Jun 2022, Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ACRS) was held by 112 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 63,269,555 shares. The largest 10 holders included WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., VR Adviser, LLC, RA CAPITAL MANAGEMENT, L.P., BVF INC/IL, Rock Springs Capital Management LP, VANGUARD GROUP INC, Foresite Capital Management IV, LLC, COMMODORE CAPITAL LP, and ORBIMED ADVISORS LLC. This page lists 112 institutional shareholders reporting positions in this security for the Q2 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders

107

Q2 2022 holders

112

Holder diff

Investor	Q1 2022 Shares	Q2 2022 Shares	Share Diff	Share Chg %	Q1 2022 Value $	Q2 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.